Oncosec Medical (ONCS) Reports Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab
Tweet Send to a Friend
OncoSec Medical Incorporated (NASDAQ: ONCS) today announced updated Phase 2 clinical and immune monitoring data from patients treated with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
